Search

Your search keyword '"Mallath, M"' showing total 4 results
Start Over Author "Mallath, M" Topic medicine.disease
4 results on '"Mallath, M"'

1. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors

Author

Kos Kudła, B, O'Toole, D, Falconi, Massimo, Gross, D, Klöppel, G, Sundin, A, Ramage, J, Oberg, K, Wiedenmann, B, Komminoth, P, Van Custem, E, Mallath, M, Papotti, M, Caplin, M, Arnold R, Palma de Mallorca Consensus Conference P. a. r. t. i. c. i. p. a. n. t. s., Buscombe, J, Chen, Yj, Cioppi, F, de Herder, W, Eriksson, B, Fazio, N, Grossman, A, Kaltsas, G, Kianmanesh, R, Kulke, M, Kwekkeboom, D, Lebtahi, R, Lesurtel, M, Lind, P, Lopes, Jm, Nilsson, O, O'Connor, J, Pape, Uf, Pavel, M, Perren, A, Plöckinger, U, Rindi, G, Ruszniewski, P, Sasano, H, Scoazec, Jy, Sevilla Garcia, I, Steinmüller, T., Kos Kudła, B, O'Toole, D, Falconi, Massimo, Gross, D, Klöppel, G, Sundin, A, Ramage, J, Oberg, K, Wiedenmann, B, Komminoth, P, Van Custem, E, Mallath, M, Papotti, M, and Caplin, M.

Subjects
medicine.medical_specialty, Pathology, Lung Neoplasms, Endocrinology, Diabetes and Metabolism, Lung metastasis, MEDLINE, Bone Neoplasms, Digestive System Neoplasms, Humans, Neuroendocrine Tumors, Neuroendocrine tumors, Cellular and Molecular Neuroscience, Endocrinology, Internal medicine, medicine, Lung, Endocrine and Autonomic Systems, business.industry, Respiratory disease, Cancer, respiratory system, medicine.disease, respiratory tract diseases, medicine.anatomical_structure, Lung disease, business
Abstract

ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors

Published
2010

2. ENETS consensus guidelines for the management of patients with rare metastases from digestive neuroendocrine tumors: rationale and working framework. Introduction

Author

O'Toole, D, Rindi, G, Plã¶ckinger, U, Wiedenmann, B, Collaborators: Arnold, R, Buscombe, J, Caplin, M, Chen, Yj, Cioppi, F, de Herder, W, Eriksson, B, Falconi, Massimo, Fazio, N, Gross, D, Grossman, A, Kaltsas, G, Kianmanesh, R, Kloppel, G, Komminoth, P, Kos Kuda, B, Kulke, M, Kwekkeboom, D, Lebtahi, R, Lesurtel, M, Lind, P, Lopes, Jm, Mallath, M, Nikou, G, Nilsson, O, Oberg, K, O'Connor, J, Pape, Uf, Papotti, M, Pavel, M, Perren, A, Ploeckinger, U, Ramage, J, Ruszniewski, P, Sasano, H, Scoazec, Jy, Sevilla Garcia, I, Steinmuller, T, Sundin, A, Van Cutsem, E, O'Toole, D., O'Toole, D, Rindi, G, Plöckinger, U, Wiedenmann, B, Enets, Collaborator, and Falconi, Massimo

Subjects
medicine.medical_specialty, Endocrine and Autonomic Systems, business.industry, Consensus Development Conferences as Topic, Endocrinology, Diabetes and Metabolism, Guidelines as Topic, Neuroendocrine tumors, Digestive System Neoplasms, medicine.disease, Humans, Neoplasm Metastasis, Neuroendocrine Tumors, Cellular and Molecular Neuroscience, Endocrinology, Internal medicine, medicine, business
Published
2010

3. ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors

Author

Pavel, M, Grossman, A, Arnold, R, Perren, A, Kaltsas, G, Steinmüller, T, de Herder, W, Nikou, G, Plöckinger, U, Lopes, Jm, Sasano, H, Buscombe, J, Lind, P, O'Toole, D, Oberg, K, Collaborators: Caplin M, Palma de Mallorca Consensus Conference P. a. r. t. i. c. i. p. a. n. t. s., Chen, Yj, Cioppi, F, Eriksson, B, Falconi, M, Fazio, N, Gross, D, Kianmanesh, R, Komminoth, Gp, Kos Kudła, B, Kulke, M, Kwekkeboom, D, Lebtahi, R, Lesurtel, M, Mallath, M, Nilsson, O, O'Connor, J, Pape, Uf, Papotti, Mauro Giulio, Ramage, J, Rindi, G, Ruszniewski, P, Scoazec, Jy, Sevilla Garcia, I, Sundin, A, Van Cutsem, E, Wiedenmann, B., Erasmus MC other, Internal Medicine, M, Pavel, A., Grossman, R., Arnold, A., Perren, G., Kaltsa, T., Steinmüller, W. d., Herder, G., Nikou, U., Plöckinger, J. M., Lope, H., Sasano, J., Buscombe, P., Lind, D., O'Toole, K., Oberg, and Falconi, Massimo

Subjects
endocrine system, medicine.medical_specialty, Pathology, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Brain Neoplasms, Digestive System Neoplasms, Female, Heart Neoplasms, Humans, Neuroendocrine Tumors, Ovarian Neoplasms, Ovary, Neuroendocrine tumors, Metastasis, Cellular and Molecular Neuroscience, Heart neoplasms, Endocrinology, Internal medicine, medicine, Endocrine and Autonomic Systems, business.industry, Cancer, medicine.disease, female genital diseases and pregnancy complications, ddc, medicine.anatomical_structure, cardiovascular system, business
Abstract

ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors

Published
2010
Full Text
View/download PDF

4. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors

Author

Clarisse Dromain, Marianne E. Pavel, Philippe Ruszniewski, Alison Langley, Christine Massien, Eric Baudin, Martyn E. Caplin, on behalf of the CLARINET Study Group, CLARINET Study Group, Raderer, A.M., Borbath, B.I., Ysebaert, D., Sedláčková, E., Vítek, P., Grønbæk, D.H., Adenis, F.A., Buscail, L., Cadiot, G., Dominguez, S., Ducreux, M., Lombard-Bohas, C., Mitry, E., Ruszniewski, P., Seitz, J.F., Begum, N., Harsch, I., Pavel, M., Schöfl, C., Weber, M., Wiedenmann, B., Mallath, M., Patil, P., Sambasivaiah, K., Saxena, R., Bajetta, E., Buonadonna, A., Buzzoni, R., Cannizzaro, R., Colao, A., De Angelis, C., Tomassetti, P., Ćwikła, J., Kos-Kudła, B., Salek, S.T., Capdevila, J., Soler, G., Tabernero, J.M., Ahlman, H., Kjellman, M., Aithal, G., Anthoney, A., Caplin, M., Grossman, A., Newell-Price, J., Ramage, J., Reed, N., Rees, A., Steward, W., Wall, L., Choti, M., Phan, A.T., and Wolin, E.M.

Subjects
0301 basic medicine, Male, Cancer Research, Neuroendocrine tumors, Lanreotide, Gastroenterology, chemistry.chemical_compound, Tumor growth rate, 0302 clinical medicine, Medizinische Fakultät, Interquartile range, Medicine, Prognostic factor, Neuroendocrine Tumors/mortality, Hazard ratio, Prognosis, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Primary tumor, Tumor Burden, Neuroendocrine Tumors, Oncology, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Disease Progression, Female, Research Article, medicine.medical_specialty, Randomization, Placebo, lcsh:RC254-282, 03 medical and health sciences, Neuroendocrine tumor, Humans, Intestinal Neoplasms/mortality, Intestinal Neoplasms/pathology, Neoplasm Grading, Neoplasm Staging, Neuroendocrine Tumors/pathology, Pancreatic Neoplasms/mortality, Pancreatic Neoplasms/pathology, Proportional Hazards Models, RECIST, Internal medicine, Intestinal Neoplasms, Genetics, ddc:610, business.industry, fungi, medicine.disease, Pancreatic Neoplasms, 030104 developmental biology, chemistry, business
Abstract

Lanreotide depot/autogel antitumor activity in intestinal/pancreatic neuroendocrine tumors (NETs) was demonstrated in the phase-3 CLARINET study (NCT00353496), based on significantly prolonged progression-free survival (PFS) versus placebo. During CLARINET, patients with metastatic intestinal/pancreatic NETs received lanreotide depot/autogel 120 mg or placebo every 4 weeks for 96 weeks. Imaging data (response evaluation criteria in solid tumors [RECIST] v1.0, centrally reviewed) were re-evaluated in this post hoc analysis of tumor growth rate (TGR) in NETs. TGR (%/month) was calculated from two imaging scans during relevant periods: pre-treatment (TGR 0 ); 12-24 weeks before randomization versus baseline; each treatment visit versus baseline (TGR Tx-0 ); between consecutive treatment visits (TGR Tx-Tx ). To assess TGR as a measure of prognosis, PFS was compared for TGR 0 subgroups stratified by optimum TGR 0 cut-off; a multivariate analysis was conducted to identify prognostic factors for PFS. TGR 0 revealed tumors growing during pre-treatment (median [interquartile range] TGR 0 : lanreotide 2.1%/month [0.2; 6.1]; placebo 2.7%/month [0.15; 6.8]), contrary to RECIST status. TGR was significantly reduced by 12 weeks with lanreotide versus placebo (difference in least-square mean TGR 0-12 of - 2.9 [- 5.1, - 0.8], p = 0.008), a difference that was maintained at most subsequent visits. TGR 0 > 4%/month had greater risk of progression/death than ≤4%/month (hazard ratio 4.1; [95% CI 2.5-6.5]; p 0 , hepatic tumor load, and primary tumor type were independently associated with PFS. TGR provides valuable information on tumor activity and prognosis in patients with metastatic intestinal/pancreatic NETs, and identifies early lanreotide depot/autogel antitumor activity. Retrospective registration, 18 July 2006; EudraCT: 2005-004904-35; ClinicalTrials.gov: NCT00353496 .

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results